BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.

Analyst Reco. Biohaven Pharmaceutical Holding Company Ltd.

Equities

BHVN

VGG111961055

Market Closed - Nyse Other stock markets 21:00:02 01/05/2024 BST			5-day change	1st Jan Change
40.18 ^USD	+3.56%		+3.77%	-73.53%

04-25	Biohaven Insider Bought Shares Worth $999,169, According to a Recent SEC Filing	MT
04-23	Biohaven Shares Rise After Closing of Public Offering, Disclosure of Stock Purchase by CEO	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Biohaven Insider Bought Shares Worth $999,169, According to a Recent SEC Filing	04-25	MT
UBS Adjusts Biohaven Price Target to $60 From $59, Maintains Buy Rating	04-23	MT
Biohaven Launches $200 Million Common Stock Offering	04-17	MT
HC Wainwright Adjusts Biohaven's Price Target to $63 From $50, Maintains Buy Rating	03-04	MT
TD Cowen Ups Price Target on Biohaven to $55 From $35, Keeps Outperform Rating	03-01	MT
RBC Trims Price Target on Biohaven to $61 From $62, Keeps Outperform, Speculative Risk	03-01	MT
RBC Initiates Biohaven at Outperform With Speculative Risk, Sets Price Target at $62, Sees 'Significant Value to Be Unlocked' Over Long Term	02-16	MT
UBS Adjusts Initiates Biohaven Pharmaceutical Holding With Buy Rating, $59 Price Target	02-06	MT
Baird Starts Biohaven Pharmaceutical With Outperform Rating, $58 Price Target	12-08	MT
JPMorgan Adjusts Biohaven Pharmaceutical Price Target to $32 From $26, Maintains Overweight Rating	11-20	MT
Piper Sandler Adjusts Price Target on Biohaven Pharmaceutical to $36 From $29, Keeps Overweight Rating	11-15	MT
JPMorgan Adjusts Price Target on Biohaven Pharmaceutical Holding to $24 From $27, Maintains Overweight Rating	16/08/23	MT
Cantor Fitzgerald Raises Price Target on Biohaven Pharmaceutical to $31 From $27, Maintains Overweight Rating	04/04/23	MT
SVB Leerink Initiates Biohaven at Outperform With $24 Price Target	24/01/23	MT
JPMorgan Starts Biohaven Pharmaceutical Holding at Overweight With $23 Price Target	04/01/23	MT
BTIG Starts Biohaven Pharmaceutical Holding at Buy With $24 Price Target	02/12/22	MT
William Blair Initiates Biohaven Pharmaceutical Holding Company With Outperform Rating	10/11/22	MT
Piper Sandler Adjusts Price Target on Biohaven Pharmaceutical to $21 From $23, Reiterates Overweight Rating	26/10/22	MT
Piper Sandler Initiates Biohaven at Overweight with $23 Price Target	12/10/22	MT
Piper Sandler Downgrades Biohaven Pharmaceutical to Neutral From Overweight, Maintains $149 Price Target	19/08/22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Biohaven Pharmaceutical Holding Company Ltd.

Equities

BHVN

VGG111961055

Analyst Reco.

Filters